Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Atropine use may prevent myopic progression in children

04 Dec 2017

The use of atropine appears to prevent myopic progression, as supported by level I evidence, according to a recent study. Additionally, myopic rebound has been reported after treatment discontinuation, but this is minimized by using low doses, particularly atropine 0.01%.

Researchers conducted literature searches in PubMed and the Cochrane Library databases to examine the efficacy of topical atropine for the prevention of myopic progression in children. A total of 98 citations were identified, of which 23 were reviewed in full text. Seventeen of these articles were then included in the assessment and subsequently assigned a level of evidence (I, II or III) rating by the panel methodologist.

Most studies reported less myopic progression in children administered with atropine vs controls. Eight of the level I and II studies that evaluated primarily myopic progression also reported less myopic progression with atropine (myopic progression ranging from 0.04 to 0.47 dioptres [D]/year) vs controls (0.38 to 1.19 D/year).

Studies evaluating myopic progression after treatment cessation reported a rebound effect. There were also some studies that assessed the optimal dosage of atropine for the prevention of myopic progression, rebound after discontinuation of treatment and minimization of side effects.

Atropine at lower dosages (0.5%, 0.1% and 0.01%) was slightly less effective during treatment periods of 1 to 2 years, but it was likely to result in less rebound myopic progression (mean myopic progression after treatment cessation, 0.28 vs 0.87 D/year for atropine 0.01% and 0.5%, respectively), fewer side effects and similar long-term results for myopic progression after the study period and rebound effect were considered.

“The most robust and well-designed studies were carried out in Asian populations,” researchers said. “Studies involving patients of other ethnic backgrounds failed to provide sufficient evidence of an effect of atropine on myopic progression.”

Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.